Application

Anti-VGLUT2, clone 8G9.2 ZooMAb, Cat. No. ZMS1026, is a recombinant Mouse monoclonal antibody that targets Vesicular glutamate transporter 2 and is tested in Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), and Western Blotting.

Immunofluorescence Analysis: A 1:1,000 dilution from a representative lot detected VGLUT2 in rat brain tissue sections.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected VGLUT2 in SH-SY5Y cells. Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected VGLUT2 in rat hippocampus and human cerebral cortex tissue sections.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

Full-length recombinangt Rat Vesicular Glutamate Transporter 2 (VGLUT2).

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant mouse monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 8G9.2 is a ZooMAb mouse recombinant monoclonal antibody that specifically detects Vesicular Glutamate Transporter 2.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Vesicular glutamate transporter 2 (UniProt Q9JI12; also known as Differentiation-associated BNPI, Differentiation-associated Na(+)-dependent inorganic phosphate cotransporter, Solute carrier family 17 member 6, VGluT2) is encoded by the Slc17a6 (also known as Dnpi, Vglut2) gene (Gene ID: 84487) in rat. VGluT2 is a multi-pass membrane protein that mediates the uptake of glutamate into synaptic vesicles at presynaptic nerve terminals of excitatory neurons. Its N- and C-terminal tails (aa 1-71 and 499-582, respectively) are exposed at the cytoplasmic side. VGLUT1- and VGLUT2-expressing neurons represent the bulk of canonical glutamatergic neurons in the brain, with VGLUT1 representing the major subtype and accounting for approximately 80% of total vesicular transport of glutamate in the brain. Expression of VGLUT2 is reported to increase sharply during the first ten days of postnatal life, and also increases with increasing numbers of rhodopsin cells in the retina. It has been shown that both VGLUT1 and VGLUT2 are expressed prominently in the adult brain, however, during the first two weeks of postnatal development, VGLUT2 expression predominates. VGLUT1 expression becomes essential for survival at the time of the developmental switch from VGLUT2 to VGLUT1. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.